Nature Search

Genomic risk model to implement precision prostate cancer screening in clinical care: the ProGRESS study

Vassy, Dornisch and colleagues developed a genomics-based prostate cancer risk model to support a randomized clinical trial of precision screening in a national healthcare system.

Jason L. Vassy
Anna M. Dornisch
Tyler M. Seibert
Research26 Jan 2026
Nature Cancer

P: 1-16
Feasibility and outcomes of the DNA Screen nationwide adult genomic screening pilot

A prospective nationwide genomic screening pilot for ten genes in young adults in Australia detected pathogenic variants in 2% of the population, most of whom were ineligible for government-funded genomic testing.

Paul Lacaze
Jane Tiller
Ingrid Winship
Research15 Jan 2026
Nature Health

Volume: 1, P: 90-98
Development of a clinical polygenic risk score assay and reporting workflow

The first report from the prospective GenoVA Study provides preliminary insights into the development of a polygenic risk score assay in a clinical setting and discusses the challenges of generating, interpreting and reporting results.

Limin Hao
Peter Kraft
Matthew S. Lebo
ResearchOpen Access18 Apr 2022
Nature Medicine

Volume: 28, P: 1006-1013
Clinical translation of polygenic scores for prostate cancer screening

In this Review, the authors describe standards informing the development and use of polygenic scores and illustrate their application to advance the clinical translation of polygenic scores to precision prostate cancer screening.

Dmitry Ratner
Jason L. Vassy
Reviews13 Oct 2025
Nature Reviews Urology

P: 1-10
Susceptibility to type 2 diabetes mellitus—from genes to prevention

Advances in the field of genetics have enabled the discovery of numerous loci associated with type 2 diabetes mellitus (T2DM). This Review examines current knowledge about T2DM genetic risk prediction, the effect of lifestyle intervention according to genetic risk and the role of genetic counselling to support behavioural modification.

Marie-France Hivert
Jason L. Vassy
James B. Meigs
Reviews18 Feb 2014
Nature Reviews Endocrinology

Volume: 10, P: 198-205
Secondary findings from clinical genomic sequencing: prevalence, patient perspectives, family history assessment, and health-care costs from a multisite study

M. Ragan Hart
Barbara B. Biesecker
Lucia A. Hindorff
Research05 Oct 2018
Genetics in Medicine

Volume: 21, P: 1100-1110
Perceived benefits and barriers to implementing precision preventive care: Results of a national physician survey

Jason L. Vassy
Benjamin J. Kerman
Charles A. Brunette
Research20 Feb 2023
European Journal of Human Genetics

Volume: 31, P: 1309-1316
Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial

Kurt D Christensen
Jason L Vassy
Dmitry Dukhovny
Research22 Mar 2018
Genetics in Medicine

Volume: 20, P: 1544-1553
The frequency of pathogenic variation in the All of Us cohort reveals ancestry-driven disparities

A comparison of the frequency of pathogenic mutations in 73 genes in the All of Us cohort highlights the differences in pathogenic variation attributed to ancestry.

Eric Venner
Karynne Patterson
Miriam Vos
ResearchOpen Access19 Feb 2024
Communications Biology

Volume: 7, P: 1-11
Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee

Jason L. Vassy
Annjanette Stone
Steven A. Schichman
Research01 Jun 2018
Genetics in Medicine

Volume: 21, P: 382-390
Correction: Secondary findings from clinical genomic sequencing: prevalence, patient perspectives, family history assessment, and health-care costs from a multisite study

M. Ragan Hart
Barbara B. Biesecker
Lucia A. Hindorff
Amendments and Corrections22 Jan 2019
Genetics in Medicine

Volume: 21, P: 1261-1262
Response to Gammal et al.

Jason L. Vassy
Annjanette Stone
Steven A. Schichman
Correspondence12 Jan 2019
Genetics in Medicine

Volume: 21, P: 1888-1889
Airmen and health-care providers’ attitudes toward the use of genomic sequencing in the US Air Force: findings from the MilSeq Project

Stacey Pereira
Rebecca L. Hsu
Amy L. McGuire
Research18 Aug 2020
Genetics in Medicine

Volume: 22, P: 2003-2010
Prescription medication changes following direct-to-consumer personal genomic testing: findings from the Impact of Personal Genomics (PGen) Study

Deanna Alexis Carere
Tyler J. VanderWeele
Robert C. Green
Research22 Sept 2016
Genetics in Medicine

Volume: 19, P: 537-545

Search

Genomic risk model to implement precision prostate cancer screening in clinical care: the ProGRESS study

Feasibility and outcomes of the DNA Screen nationwide adult genomic screening pilot

Development of a clinical polygenic risk score assay and reporting workflow

Clinical translation of polygenic scores for prostate cancer screening

Susceptibility to type 2 diabetes mellitus—from genes to prevention

Secondary findings from clinical genomic sequencing: prevalence, patient perspectives, family history assessment, and health-care costs from a multisite study

Perceived benefits and barriers to implementing precision preventive care: Results of a national physician survey

Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial

The frequency of pathogenic variation in the All of Us cohort reveals ancestry-driven disparities

Pharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee

Correction: Secondary findings from clinical genomic sequencing: prevalence, patient perspectives, family history assessment, and health-care costs from a multisite study

Response to Gammal et al.

Airmen and health-care providers’ attitudes toward the use of genomic sequencing in the US Air Force: findings from the MilSeq Project

Prescription medication changes following direct-to-consumer personal genomic testing: findings from the Impact of Personal Genomics (PGen) Study

Search

Quick links

Search

Filter By:

Search

Quick links